During the past decade, Hebei Yanda Ludaopei Hospital conducted 38 clinical trials. In the 10-year time frame, 38 clinical trials started and 1 clinical trials were completed, i.e. on average, 2.6% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 1 clinical trials were completed. i.e. 3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hebei Yanda Ludaopei Hospital" #1 sponsor was "Hebei Yanda Ludaopei Hospital" with 14 trials, followed by "Hebei Senlang Biotechnology Inc., Ltd." with 13 trials sponsored, "Beijing Doing Biomedical Co., Ltd." with 2 trials sponsored, "iCell Gene Therapeutics" with 2 trials sponsored and "Bioceltech Therapeutics, Ltd." with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hebei Yanda Ludaopei Hospital" #1 collaborator was "Hebei Yanda Ludaopei Hospital" with 11 trials as a collaborator, "China Immunotech (Beijing) Biotechnology Co., Ltd." with 7 trials as a collaborator, "Beijing Lu Daopei Hospital" with 5 trials as a collaborator, "Gracell Biotechnology Ltd." with 5 trials as a collaborator and "iCar Bio Therapeutics" with 2 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Hebei Yanda Ludaopei Hospital" are "B-cell Acute Lymphoblastic Leukemia" (5 trials), "B-ALL" (3 trials), "Leukemia" (3 trials), "Lymphoma" (3 trials) and "Multiple Myeloma" (2 trials). Many other conditions were trialed in "Hebei Yanda Ludaopei Hospital" in a lesser frequency.

Most popular intervention types in "Hebei Yanda Ludaopei Hospital" are "Biological" (36 trials), "Drug" (3 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "CD19 CAR-T" (2 trials), "CD19/CD20 Dual-CAR-T cells" (2 trials), "GC022F" (2 trials), "Anti-CD19-CAR" (1 trials) and "Autologous CAR-T cells" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hebei Yanda Ludaopei Hospital" are 38 trials for "All" genders.

Currently, there are NaN active trials in "Hebei Yanda Ludaopei Hospital". 2 are not yet recruiting, 5 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Hebei Yanda Ludaopei Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hebei Yanda Ludaopei Hospital, 21 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 9 trials that are defined as “Not Applicable".